Please use this identifier to cite or link to this item:
Title: Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era
Authors: Cömert, Melda
Baran, Yusuf
Saydam, Güray
Ege Üniversitesi
Izmir Institute of Technology
Ege Üniversitesi
Keywords: Chronic myeloid leukemia
Moleculer biology
Imatinib mesylate
Issue Date: 2013
Publisher: e-Century Publishing Corporation
Abstract: Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by a reciprocal translocation between long arms of chromosomes 9 and 22 t(9; 22) that generates the BCR-ABL fusion gene. If left untreated, newly diagnosed chronic phase CML patients finally progress to accelerated and blastic phase. After the introduction of tyrosine kinase inhibitors (TKIs), treatment strategies of CML changed dramatically. However, the development of resistance to TKIs started to create problems over time. In this review, the current information about CML biology before and after imatinib mesylate treatment is summarized.
Appears in Collections:Molecular Biology and Genetics / Moleküler Biyoloji ve Genetik
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection

Files in This Item:
File Description SizeFormat 
ajbr0003-0191.pdfReview Article529.06 kBAdobe PDFView/Open
Show full item record

CORE Recommender


checked on Jan 27, 2024

Page view(s)

checked on Feb 19, 2024


checked on Feb 19, 2024

Google ScholarTM


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.